Skip to main content
. Author manuscript; available in PMC: 2012 Jul 15.
Published in final edited form as: Free Radic Biol Med. 2011 Apr 22;51(2):299–313. doi: 10.1016/j.freeradbiomed.2011.04.013

Table 2.

GSTP1 polymorphisms in cancer susceptibility and therapy

Allele ↑ Cancer risk Variation & survival following therapy Refs
I105/A114
(GSTP1*A)		 Hodgkin’s
Lymphoma		 Val 105                  ------------5-year survival↑ [100,
183]
Val105
(GSTP1*B
and
GSTP1*C)		 Breast cancer Val105                   ------------OS↑ [102,
184]
CML Val105       ------------ Poor or minor response [185]
Endometrial cancer No report [186]
HCC Val105                   ------------OS↓ [187]
Pancreatic cancer Val105/Val114       ------------OS↑ [188,
189]
Val114
(GSTP1*C and
GSTP1*D)		 Esophageal cancer Val105, Val11 4     ------------OS↓, Recurrence
rate↑		 [190–
193]
No definitive
correlation
with GSTP1
polymorphisms		 Colorectal cancer Val105                   ------------ Controversial [104,
194,
195]
Val114                   ------------Neurotoxicity↑
Gastric cancer Val105             ------------OS↑, Neurotoxicity↓ [103,
196]
Glioma Ile105/Ala114        -----------OS↑, Toxicity↑ [96, 97,
107]
Val105/Val114       ------------OS↑, Toxicity↓
Lung cancer Val114                   ------------OS↑ [197–
199]
Multiple Myeloma Val105                   ------------OS↑ [200,
201]
Ovarian cancer Val105                   ------------OS↑ [104,
202]

OS, overall survival; CML, chronic myeloid leukemia; HCC, hepatocellular carcinoma.